imaging of




At Fuzionaire Diagnostics, our mission is to develop new molecular imaging agents capable of changing the medical management of significant, chronic human diseases by identifying the first stages of pathological change, potentially assisting in earlier diagnosis, and better management and development of new therapies.

Our proprietary technology applies to radiochemistry the breakthrough featured in the Caltech film Element 19, which enables record-breaking, ultra-fast radiolabeling efficiency and the ability to bioconjugate new molecules.


From a Nobel Prize-winning lab at Caltech and the Crump Institute at UCLA, and with an advisory team that includes the inventor of positron emission tomography (PET) and the PET scanner, our award-winning work transforms what is possible in the diagnosis and treatment of cancer and other diseases.